Cellbricks

Cellbricks is a German biotech startup founded in 2015 with a visionary slogan of "Cellbricks envisions a future where 3D-bioprinting of human tissue and organs is a common medical practice." The company is dedicated to revolutionizing healthcare by pioneering the production of bioprinted tissue therapeutics to address compromised organ function, ultimately aiming to extend and enhance the lives of millions of patients. Combining expertise in synthetic biology and 3D-bioprinting, Cellbricks has developed proprietary biofabrication technology and tissue engineering proficiency to replicate human tissue at scale. This breakthrough allows researchers and doctors to provide more effective clinical treatments for patients. The company's recent Venture Round investment at 31 December 2022 was led by Brooks Hill Partners, signifying confidence from the investment community in Cellbricks' potential. With its headquarters in Berlin, a thriving startup hub in Europe, Cellbricks has attracted a diverse and talented team of biotech enthusiasts, scientists, PhDs, engineers, and entrepreneurs from top universities and companies worldwide. This distinctive combination of advanced technology, strategic location, and interdisciplinary talent positions Cellbricks as a promising player in the biotechnology and manufacturing industries. For further inquiries, interested parties can reach out to Moritz Marschall at [email protected].